Portfolio
Alyssum is developing a B cell-based cancer therapy.
Evommune is developing therapies to treat chronic inflammatory diseases.
Mendaera is developing a handheld device integrating robotics, AI, and real-time imaging to improve needle-based procedures such as biopsies.
Brixton Biosciences is developing an injectable Neural Ice™ for pain relief initially in osteoarthritis of the knee and lateral hip pain.
Imperative Care is developing innovations for patients suffering from vascular diseases including strokes and pulmonary embolisms.
Cercle’s AI solution interprets real world data to improve outcomes starting with fertility.
Kanvas is developing microbiome therapies for various indications including cancers and inflammatory bowel disease.
Reunion Neuroscience’s lead asset is a fast-acting and durable antidepressant for patients suffering from postpartum depression.
IgGenix is developing a monoclonal antibody-based approach to treating peanut allergies.
Gynesonics (acquired)
Gynesonics’ Sonata® System is an incision-free option for treating symptomatic uterine fibroids.
Sequel is developing the next generation of diabetes management solutions.
inSoma Bio’s Fractomer™ technology is an injectable gel that improves breast reconstruction outcomes post lumpectomy.
AOA Dx is developing a diagnostic test to detect ovarian cancer at early stages.
Rejoni is developing a hydrogel product to prevent intrauterine adhesions after uterine surgery.
Nymbl is a digital app that improves balance to prevent falls for older adults.
Raydiant Oximetry’s technology is designed to more accurately detect fetal distress during labor.
BioAesthetics is creating a replacement nipple for post-mastectomy patients.
Next